Melody Cobleigh to Prospective Studies
This is a "connection" page, showing publications Melody Cobleigh has written about Prospective Studies.
Connection Strength
0.311
-
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113.
Score: 0.120
-
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441.
Score: 0.113
-
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021 Jul; 188(1):179-190.
Score: 0.033
-
Hormone replacement therapy and high S phase in breast cancer. JAMA. 1999 Apr 28; 281(16):1528-30.
Score: 0.029
-
Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec; 28 Suppl 1:S39-47.
Score: 0.016